Argenx buys into macrocyclic peptides with $1.15bn UNP deal
Argenx has announced the acquisition of Unnatural Products, bringing the Santa Cruz biotech's macrocyclic peptide platform in
DO
By Daniel Okafor · Regulatory Correspondent
Nov 9 07:05 ETSource: BioXconomy
From the source
Read at bioxconomy.comArgenx buys into macrocyclic peptides with $1.15bn UNP deal
Argenx has announced the acquisition of Unnatural Products, bringing the Santa Cruz biotech's macrocyclic peptide platform in house.
